The B4GALT1 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma TE1 cell line. This product is generated by introducing CRISPR/Cas9-mediated gene disruption targeting the B4GALT1 locus, resulting in a heterogeneous pool of cells harboring diverse loss-of-function mutations. As a polyclonal preparation, the cells retain genetic heterogeneity while collectively abolishing B4GALT1-dependent galactosyltransferase activity. This format is particularly suited for studying the functional consequences of B4GALT1 ablation in a cancer-relevant background without the biases introduced by clonal selection, enabling robust assessment of glycan-dependent phenotypes in esophageal squamous cell carcinoma research.
The TE1 cell line is a well-characterized model of human esophageal squamous cell carcinoma, established from a well-differentiated primary tumor. These adherent epithelial cells are extensively used in cancer research for studying carcinogenesis, drug responses, and signal transduction. The use of TE1 as the parental line ensures that B4GALT1 disruption is studied in a context that closely mimics the glycobiology of esophageal tumors.
B4GALT1 encodes a Golgi ??-1,4-galactosyltransferase that transfers galactose from UDP-galactose to N-acetylglucosamine, generating Gal??1-4GlcNAc termini on glycoproteins and glycolipids. Its expression is regulated by Sp1 and activated by prolactin receptor signaling, TGF-??, and NF-??B. Key downstream targets include integrin ??1 and EGFR, whose glycosylation by B4GALT1 modulates their function. The enzyme interacts with alpha-lactalbumin in lactose synthesis and with the UDP-galactose transporter SLC35A2. In the Golgi, B4GALT1 cooperates with other glycosyltransferases to generate ligands for galectin-1, which binds these epitopes to activate integrin-mediated signaling cascades involving focal adhesion kinase (FAK). Disruption of this pathway severs the link between extracellular matrix cues and intracellular responses.
In TE1 cells, B4GALT1 knockout ablates terminal galactosylation, impairing galectin-1 binding and attenuating integrin ??1 activation and FAK signaling. This loss disrupts cell adhesion to laminin and reduces migratory capacity, directly linking glycosylation defects to attenuated tumor cell behavior. The model also serves as a tool for congenital disorder of glycosylation type IId (CDG-IId) caused by B4GALT1 mutations, and it enables dissection of galactose-dependent mechanisms in esophageal squamous cell carcinoma progression.
Critical applications include confirmation of B4GALT1 loss by Western blot, evaluation of Gal??1-4GlcNAc reduction via RCA-I/ECL lectin blotting and flow cytometry, and functional assays such as laminin/galectin-1 adhesion, wound-healing migration, and MTT proliferation. Transcriptomic analysis via RNA-seq can reveal compensatory network rewiring. This polyclonal knockout population is ideally suited for drug target discovery, investigation of glycosylation inhibitors, and mechanistic studies of the B4GALT1/galectin-1/integrin/FAK axis. Contact Ascent Research for further information.
